Sunday, November 16, 2025 11/16/2025

Framework to Accelerate Substance Use Disorder Genetic Studies through Customizable, EHR-Based Precision Phenotyping

Award Number: DP1DA056667
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Framework to Accelerate Substance Use Disorder Genetic Studies through Customizable, EHR-Based Precision Phenotyping - Project Summary/Abstract There is a critical need for accurate, efficient, and portable substance use disorder (SUD) identification methods that support large-scale genetic studies in uncovering biological mechanisms helpful in SUD prevention and management. The long-term goal of this work is to support genetic discovery efforts that result in beneficial interventions for prevention and treatment of SUD. The overall objective in this proposal is to develop and evaluate an SUD phenotyping method that allows investigators to fine-tune phenotypes for their specific projects. Given most large-scale SUD phenotyping for genetics studies have relied on administrative billing codes (that undercount true cases) and binary outcome labels (that induce arbitrary dichotomization), the rationale for this project is that a system which includes a variety of data sources and generates a probabilistic outcome along a continuum is needed. The SUD phenotyping framework will support the inclusion of heterogenous electronic health record data types (including administrative billing codes, medication information, and unstructured text data) and will be evaluated in multiple organizations. Pairing these SUD phenotypes with genetic data will enhance our understanding of SUD mechanisms among individuals. That foundational work could ultimately result in the development of polygenic risk scores and clinical decision support systems that we could implement prospectively in clinical care. The proposed research is significant because researchers have a pressing need for SUD phenotyping approaches that can be customized to their research focus and available data. This proposal’s innovation lies in the creation of a “self-service” approach to SUD phenotype development in which a research team can specify their own phenotype definitions. The software will have a graphical user interface that makes the highest-yield rules/heuristics the easiest to use and can therefore be used by investigators with basic scientific programming knowledge. Through the activities outlined above, this innovation will directly accelerate genetic studies of SUD while simultaneously developing a precision phenotyping framework that can be applied to other disease domains.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $574,501 )
2025	2025	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Drug Use and Addiction Research Programs	005	5	8/7/2025	NON-COMPETING CONTINUATION	$525,000
2025	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Drug Use and Addiction Research Programs	004	4	6/22/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$232,506
2025	2024	VANDERBILT UNIVERSITY	110 21ST AVE S	NASHVILLE	TN	37203	DAVIDSON	USA	Drug Use and Addiction Research Programs	003	3	6/22/2025	NON-COMPETING CONTINUATION	-$1
2025	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Drug Use and Addiction Research Programs	001	4	3/28/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$525,000
2025	2024	VANDERBILT UNIVERSITY	110 21ST AVE S	NASHVILLE	TN	37203	DAVIDSON	USA	Drug Use and Addiction Research Programs	000	3	3/28/2025	NON-COMPETING CONTINUATION	-$475,499
2025	2023	VANDERBILT UNIVERSITY	110 21ST AVE S	NASHVILLE	TN	37203	DAVIDSON	USA	Drug Use and Addiction Research Programs	002	2	6/22/2025	NON-COMPETING CONTINUATION	-$232,505
														Subtotal = $574,501

Issue Date FY: 2024 ( Subtotal = $475,500 )
2024	2024	VANDERBILT UNIVERSITY	110 21ST AVE S	NASHVILLE	TN	37203	DAVIDSON	USA	Drug Use and Addiction Research Programs	000	3	8/16/2024	NON-COMPETING CONTINUATION	$475,500
														Subtotal = $475,500

Issue Date FY: 2023 ( Subtotal = $475,500 )
2023	2023	VANDERBILT UNIVERSITY	110 21ST AVE S	NASHVILLE	TN	37203	DAVIDSON	USA	Drug Use and Addiction Research Programs	000	2	8/2/2023	NON-COMPETING CONTINUATION	$475,500
														Subtotal = $475,500

Issue Date FY: 2022 ( Subtotal = $475,500 )
2022	2022	VANDERBILT UNIVERSITY, THE	110 21ST AVENUE S STE 800	NASHVILLE	TN	37203	DAVIDSON	USA	Drug Use and Addiction Research Programs	000	1	7/25/2022	NEW	$475,500
														Subtotal = $475,500

Grand Total All Awards = $2,001,001

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Framework to Accelerate Substance Use Disorder Genetic Studies through Customizable, EHR-Based Precision Phenotyping

Award Number: DP1DA056667

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer